The membrane bound receptor tyrosine kinase Her2 is overexpressed in approximately 30% of human breast cancers, which correlates with poor prognosis. Her2induced signaling pathways include MAPK and PI3K/ Akt, of which the latter has been shown to be critical for Her2 þ breast cancer cell growth and survival. In addition, the NF-jB pathway has been shown to be activated downstream of Her2 overexpression; however, the mechanisms leading to this activation are not currently clear. Using Her2 þ /ER À breast cancer cells, we show that Her2 activates NF-jB through the canonical pathway which, surprisingly, involves IKKa. Knockdown of IKKa led to a significant decrease in transcription levels of multiple NF-jB-regulated cytokine and chemokine genes. siRNAmediated knockdown of IKKa resulted in a decrease in cancer cell invasion, but had no effect on cell proliferation. Inhibition of the PI3K/Akt pathway had no effect on NF-jB activation, but significantly inhibited cell proliferation. Our study suggests different roles for the NF-jB and PI3K pathways downstream of Her2, leading to changes in invasion and proliferation of breast cancer cells. In addition this work indicates the importance of IKKa as a mediator of Her2-induced tumor progression.
Introduction
The epidermal growth factor receptor Her2 is amplified in 20-30% of breast cancers, which typically do not express estrogen receptor, and are often correlated with poor prognosis and/or chemoresistance, making Her2 an important therapeutic target (Slamon et al., 1987 (Slamon et al., , 1989 Hynes and Stern, 1994; Klapper et al., 2000) . The Her2specific antibody trastuzumab and the dual EGFR/Her2 inhibitor lapatinib have been shown to decrease growth of Her2-overexpressing tumors (Pegram et al., 1998; Baselga et al., 1999) ; however, a majority of patients treated with trastuzamab develop resistance (Slamon et al., 2001) , indicating the importance of elucidating alternative therapeutic targets in this disease. Her2overexpression was first shown to activate NF-kB over a decade ago (Galang et al., 1996) , however, the role that NF-kB has in development and progression of Her2overexpressing breast cancer is still poorly understood. In addition, the pathway leading to NF-kB activation downstream of Her2 is not well characterized.
NF-kB is an important transcription factor that has been shown to be involved in expression of genes involved in key cellular processes including innate and adaptive immunity (Bonizzi and Karin, 2004) , cell proliferation and survival (Papa et al., 2006) , lymphoid organ development (Weih and Caamano, 2003) , as well as being activated in a variety of different cancers, including breast cancer (Cogswell et al., 2000; Basseres and Baldwin, 2006; Belguise and Sonenshein, 2007) . The NF-kB family of transcription factors consists of five subunits: RelA (p65), RelB, c-Rel, p105/p50 and p100/p52. These subunits are evolutionarily conserved and exist as hetero-or homodimers (Hayden and Ghosh, 2004) . The p65/p50 heterodimer is the most abundant NF-kB complex in the cell and is regulated by the so-called canonical pathway. Following stimulation with activators such as TNF, IkB is phosphorylated by the inhibitor of kappaB kinase (IKK) complex. The IKK complex consists of two catalytic subunits IKKa, and IKKb, and a regulatory subunit IKKg (NEMO), which binds both catalytic subunits at their NEMO-binding domain (Gilmore, 2006) . In the canonical pathway, IKKb phosphorylates IkBa leading to its degradation and NF-kB nuclear accumulation (Ghosh and Karin, 2002) . Furthermore, the p65 subunit of NF-kB can be phosphorylated on multiple residues, including serine 536, which is important for transactivation potential (Sakurai et al., 1999) . NF-kB activation can also occur via the alternative, or non-canonical pathway. Activation of NF-kB in the non-canonical pathway, most common in B cells, involves IKKa and is IkBaindependent (Solt and May, 2008) . Thus most current models place IKKb as the dominant IKK subunit in the canonical pathway with IKKa functioning in the noncanonical system. Few studies have addressed the individual roles of IKKa and IKKb downstream of oncoprotein-dependent signaling.
Using an siRNA approach, we set out to determine how NF-kB is activated downstream of Her2, and what role the IKK complex has in this signaling cascade, as well as how the activation of the IKK kinases may lead to a malignant state. Although the classical pathway has long been thought to require IKKb, here we show that IKKa has a larger role than IKKb in the activation of NF-kB in Her2 þ breast cancer cells, including the phosphorylation of the p65 subunit at serine 536. Using siRNA to the IKK kinases, we show that knockdown of IKKa leads to a change in the gene expression profile in Her2 þ cells, including a notable cytokine and chemokine gene expression signature. Furthermore, knockdown of IKKa by siRNA led to a marked decrease in invasive ability in SKBr3 cells, yet had no effect on cell proliferation. Taken together, our data suggests that Her2 can activate NF-kB through the canonical pathway. Surprisingly, this activation occurs primarily through IKKa, a subunit typically not thought to be involved in the canonical pathway. Interestingly, we have discovered differential roles for the IKK kinases with IKKa specifically involved in an invasive oncogenic phenotype in Her2 þ breast cancer cells.
Results

Lapatinib inhibits Her2 activation of NF-kB and Akt
It has previously been shown that Her2-overexpression leads to activation of NF-kB family members involved in the canonical pathway, specifically the p65/p50 heterodimeric complex (Galang et al., 1996; Biswas et al., 2004) . Given this result, we investigated whether the dual EGFR/Her2 inhibitor Lapatinib (Tykerb, GW572016) could block Her2-induced p65 phospho-rylation at serine 536, a marker of increased NF-kB transcriptional activity (Sakurai et al., 1999) . Five breast cancer cell lines were treated with 1 mM lapatinib for 12 h and whole-cell extracts were analysed for expression of phosphorylated p65. A marked decrease in p65 phosphorylation was observed in Her2-ovexpressing tumor cell lines (SKBr3 and MDA-MB-453) upon treatment with lapatinib, whereas non-Her2-overexpressing tumor cell lines (MCF7 and MDA-MB-231) showed no change (Figure 1a ). The H16N2-Her2 cell line also showed a decrease in p65 phosphorylation upon lapatinib treatment. Overexpression of Her2 in this cell line results in NF-kB activation, as the parental cell line, H16N2-pTP, has very little basal p65 phosphorylation (Supplementary Figure 1 ). To further investigate how Her2 signals to NF-kB, we chose to use the tumor-derived SKBr3 cell line, as it has previously proven to be an excellent in vitro model for Her2 þ /ER À breast cancer (Singh et al., 2007) . SKBr3 cells were treated with 1 mM lapatinib or vehicle control over a course of 24 h and whole-cell extracts were analysed for levels of phosphorylated IkBa. Phosphorylation of IkBa at serines 32 and 36 was inhibited within 3 h of lapatinib treatment ( Figure 1b ). Stabilization of IkBa was also observed, consistent with the loss of phosphorylated IkBa. It has previously been shown that Her2-overexpression activates the PI3K/Akt pathway and that lapatinib can inhibit Akt phosphorylation in lapatinib-sensitive Her2 overexpressing breast cancer cell lines (Hegde et al., 2007) . Similarly, we observe a decrease in phosphorylation of Akt at serine 473 in the lapatinib-sensitive SKBr3 cell line upon treatment with lapatinib ( Figure 1c ). This indicates that Her2 can activate both the NF-kB and the PI3K/Akt pathways, and that pharmacological inhibition of Her2 leads to subsequent inhibition of these survival pathways. Figure 1 Lapatinib treatment inhibits the NF-kB and PI3K pathways in Her2-overexpressing cells. (a) Western blot of phospho-p65 S536 in multiple breast cancer cell lines treated with lapatinib. Breast cancer cell lines were treated with 1 mM dual EGFR/Her2 inhibitor lapatinib or DMSO vehicle control for 12 h. Western blots were performed with 25 mg protein from whole-cell extracts. (b) Western blot of phospho-IkBa S32/36 in SKBr3 cells treated with lapatinib. SKBr3 cells were treated with lapatinib (1 mM) or DMSO control over a course of 24 h and levels of phospho-IkBa S32/36 were measured by western blot of 25 mg total protein from whole-cell extracts. (c) Western blot of phospho-Akt S473 in SKBr3 cells treated with lapatinib. SKBr3 cells were treated for 12 h with dual EGFR/Her2 inhibitor lapatinib and levels of phospho-Akt S473 were measured by western blot of 25 mg protein from whole-cell extracts.
Her2 activation of NF-jB through IKKa EC Merkhofer et al Her2 activates the NF-kB canonical pathway through IKKa and IKKb We next examined the role of the IKK complex in the activation of NF-kB downstream of Her2. siRNA targeting the catalytic subunits of the IKK complex (IKKa and IKKb) was transfected into Her2-overexpressing breast cancer cells and whole-cell extracts were analysed for markers of NF-kB activation. In the Her2-ovexpressing SKBr3, H16N2-Her2 and MDA-MB-453 cells, knockdown of IKKa led to a greater decrease in p65 phosphorylation than knockdown of IKKb (Figure 2a ). Mouse embryonic fibroblasts (MEFs) lacking IKKa, as well as wild-type cells, were transduced with Her2 wild-type and constitutively active constructs. Transduction of these constructs resulted in increased p65 phosphorylation in wild-type MEFs; however, no increase in phosphorylation was seen in IKKa -/-cells ( Supplementary Figure 2) . A similar result was obtained using IKKb -/-cells (data not shown), indicating that both IKKa and IKKb are important for Her2 to activate NF-kB in murine fibroblasts. To further investigate the role IKKa may have in the activation of classical NF-kB complexes downstream of Her2, siRNA was again used to target IKK in SKBr3 cells stably expressing a 3 Â kB luciferase reporter construct, as well as in H16N2- Nuclear extracts were prepared after 72 h. Identities of the bound complexes were determined by super-shift with antibodies to p65 and p50. Non-specific binding complexes are noted with as NS (d) Kinase assay measuring IKK in vitro phosphorylation of IkBa. SKBr3 cells were transfected with IKK siRNA for 72 h and IKKg was immunoprecipitated from 500 mg whole-cell extracts. Ability of immunoprecipitated complex to phosphorylate purified GST-IkBa was measured (KA). Amount of IKKa and IKKb in immunoprecipitated complex (IP) and whole-cell extracts (lysate) were measured. Fold change in kinase activity was calculated using pixel densitometry and compared with scrambled siRNA-transfected cells.
Her2 activation of NF-jB through IKKa EC Merkhofer et al Her2 and MDA-MB-453 cells transiently transfected with the 3 Â kB reporter plasmid. Knockdown of IKKa or a combination of IKKa and IKKb led to a significant decrease in luciferase reporter activity (student's t-test *o0.05 and **o0.001, respectively), whereas knockdown of IKKb did not show a significant decrease in luciferase reporter activity in two of the three cell lines (Figure 2b ). An electrophoretic mobility shift assay was performed to further investigate the role of IKK in Her2 activation of NF-kB in SKBr3 cells. Knockdown of IKKa led to a greater decrease in NF-kB DNA-binding activity than IKKb knockdown ( Figure 2c ). Supershift analysis indicated that loss of IKKa leads to a decrease in DNA binding of classical pathway NF-kB heterodimers p65/p50. Phosphorylation of IkBa by the catalytic subunits of the IKK complex is a hallmark of activation of the canonical NF-kB pathway, therefore we measured this kinase activity upon knockdown of IKKa or IKKb. The IKK complex was immunoprecipitated with IKKg, the scaffolding subunit of the IKK complex. Knockdown of IKKa led to a greater decrease of in vitro phosphorylation of IkBa than knockdown of IKKb (Figure 2d ), further indicating IKKa has a prominent role in the canonical pathway in Her2-overexpressing cells. Taken together, these results show that IKKa has a more significant role than IKKb in the activation of the NF-kB canonical pathway in Her2-overexpressing breast cancer cells.
Knockdown of IKKa and IKKb leads to distinct gene expression profiles
We next determined if knockdown of the two IKK catalytic subunits leads to differential changes in gene expression in Her2-overexpressing cells. A chemiluminescent oligo-based array was used to measure expression of 219 genes. Upon knockdown of IKKa or IKKb, significant decrease in expression was seen in 14 genes (Supplementary Table 1 ). Genes that showed significant changes in expression upon siRNA transfection were validated by quantitative real-time PCR. Decrease in expression of pro-inflammatory cytokines and chemokines IL-6, IL-8, CCL-2, TNF and the serine-protease uPA, was greater upon siRNA knockdown of IKKa than IKKb in both SKBr3 and H16N2-Her2 breast cancer cell lines (Figure 3a ). To show that IKKdependent changes in gene expression were occurring through modulation of NF-kB transcriptional activity, we performed RNAi against the classic subunit p65 in SKBr3 and H16N2-Her2 cells and assayed expression of mRNA by quantitative real-time PCR. Gene expression analysis showed that knockdown of p65 by siRNA led to a significant decrease in gene transcription levels of IL-8, IL-6, TNF and uPA (Figure 3b ). This transcriptional profile mirrors that seen upon knockdown of IKK, specifically IKKa, suggesting that induction of chemokines and cytokines in Her2 breast cancer cells occurs through IKK activation of p65. We next measured changes in expression of these genes in SKBr3 cells following treatment with lapatinib to confirm this activation of NF-kB-regulated genes was induced downstream of overexpression of Her2. Treatment of SKBr3 cells with 1 mM of lapatinib led to a significant decrease in gene expression of IL-6, IL-8, CCL-2, TNF and uPA at both 8 and 16 h post treatment (Figure 3c ). Taken together, this suggests that Her2 activates NF-kB through the canonical pathway involving IKKa and leading to an increase in multiple NF-kB-regulated genes involved in tumor progression.
Activation of NF-kB in Her2-overexpressing cells requires NEMO The scaffolding subunit of the IKK complex, IKKg (NEMO), is required for activation of NF-kB canonical pathway involving IKKb (Gilmore, 2006) , and inhibition of the IKK signalsome with the Nemo-binding domain peptide can block NF-kB activation (Biswas et al., 2004) . We used an siRNA approach to determine the importance of NEMO in NF-kB activation in Her2overexpressing cell lines. siRNA knockdown of NEMO led to a marked decrease in p65 phosphorylation in all three Her2 þ cell lines (Figure 4a ). NF-kB luciferase reporter activity was also significantly decreased in these cell lines upon siRNA knockdown of NEMO ( Figure 4b ). We performed quantitative real-time PCR analysis in the SKBr3 cell line upon NEMO knockdown to determine if this resulted in a similar gene expression profile as IKKa knockdown. Consequently, IL-6, IL-8, TNF and CCL2 all showed a significant decrease in expression upon NEMO knockdown, though uPA expression levels did not change (Figure 4c ). To rule out any effect loss of IKKa could have on non-classical activation of NF-kB, we analysed processing of the p100 subunit. Cleavage of the precursor NF-kB protein p100 to p52 is a hallmark of activation of the non-canonical pathway. No significant effect was seen on p100 processing to p52 upon knockdown of either of the IKK subunits in Her2 þ cells (Figure 4d ). These results suggest that NF-kB activation in Her2 þ cells occurs through IKKa and this requires the NEMO subunit. In addition, these results indicate that the non-canonical NF-kB-signaling pathway is not activated in Her2 þ breast cancer cells.
Activation of the NF-kB canonical pathway is independent of the PI3K pathway It was reported earlier that expression of dominantnegative PI3K and Akt plasmids can block NF-kB DNA binding downstream of Her2 (Pianetti et al., 2001) . Therefore, we investigated if NF-kB activation downstream of Her2 is dependent on the PI3K/Akt pathway. Upon treatment of SKBr3 cells with lapatinib, phosphorylation of Akt at Serine 473 decreases dramatically (Figure 1a ). Treatment with the PI3K inhibitor LY294002 also blocked phosphorylation of Akt at serine 473, however, LY294002 had no effect on the phosphorylation status of p65 at serine 536 in SKBr3, H16N2-Her2 or MDA-MB-453 cells (Figures 5a-c) . Furthermore, treatment of SKBr3 cells stably expressing the 3 Â kB luciferase reporter with LY294002 had no effect on NF-kB transcriptional activity (Figure 5d ). These results show that Her2 activates Akt through PI3K, and that the Her2-induced activation of NF-kB is independent of this pathway.
IKKa induces cell invasion but not cell proliferation
Having determined that overexpression of Her2 leads to IKKa-dependent activation of the NF-kB classical pathway, we next sought to determine how this signaling may promote oncogenic phenotypes. We investigated the effect IKK activation may have on proliferation of Her2-overexpressing breast cancer cells. SKBr3 cells were transfected with siRNA to the IKK catalytic subunits and cell proliferation was measured by MTS assay. Knockdown of IKKa or IKKb had no inhibitory effect on cell proliferation (Figure 6a ). As a control, SKBr3 cells were treated with the PI3K-inhibitor LY294002, as well as lapatinib. Inhibition of PI3K/ Akt or Her2 led to a dramatic decrease in cell growth (Figure 6b) , consistent with what has been previously reported, suggesting that Her2 drives cell proliferation through the PI3K/Akt pathway. Our previous results have shown IKK/NF-kB dependent increases in proinflammatory cytokines downstream of Her2, and these genes have been shown to promote increased motility and invasiveness. Furthermore, overexpression of Her2 has been shown to lead to increase in invasiveness of breast cancer cells (Arora et al., 2008) . We reasoned that NF-kB activity downstream of Her2 may contribute to increased invasiveness of Her2 breast cancer. To address this question, SKBr3 cells were transfected with siRNA to IKKa and IKKb and the ability of the cells to invade through a basement membrane was measured. Knockdown of IKKa led to a significant decrease in invasiveness of SKBr3 cells while knockdown of IKKb had no effect (Figure 6c ). This suggests that Her2 overexpression results in the activation of at least two independent oncogenic signaling pathways, one involving PI3K/Akt and another involving NF-kB, which have two different but important roles in promoting tumorigenesis (Figure 6d ). 
Discussion
Although Her2-positive breast cancer is known to activate both NF-kB and PI3K/Akt pathways, (Pianetti et al., 2001; Knuefermann et al., 2003; Biswas et al., 2004; She et al., 2008) , it has been unclear how Her2 induces NF-kB and whether PI3K is involved with this pathway. In addition, potential roles for IKKa and IKKb in controlling Her2-induced NF-kB have not been addressed. The latter point is of interest because IKKa and IKKb have previously been associated with controlling distinct NF-kB pathways, with IKKb controlling the so-called canonical pathway and IKKa controlling the non-canonical pathway. These issues are potentially quite important in the therapeutic setting.
Our data indicate the following: (i) IKKa has an important role in controlling the ability of Her2 to activate NF-kB through the canonical pathway (including phosphorylation of IkBa, phosphorylation of RelA/p65, activation of IKK and regulation of gene expression), (ii) IKKa controls the invasion of Her2 þ cells, with apparently little contribution of IKKb in this process and (iii) PI3K-dependent pathways do not contribute to the direct activation of NF-kB in these cells. Previous experiments from several groups have shown that IKKb has a major role in controlling canonical NF-kB activation downstream of inflammatory cytokines such as TNF (Verma et al., 1995) . The potential contribution of IKKa to NF-kB activation downstream of Her2-dependent signaling or to that induced by other oncoproteins has not been fully elucidated. Lapatinib has been shown to be effective in its inhibition of the Akt and Erk pathways in Her2 overexpressing breast cancer cell lines and human tumor xenografts, but there are no reports of it having an effect on the NF-kB pathway (Xia et al., 2002; Zhou et al., 2004) , although Herceptin has been shown to inhibit NF-kB activation (Biswas et al., 2004) . In our studies, treatment of Her2-overexpressing cell lines with 1 mM lapatinib led to a marked decrease in phosphorylation of NF-kB subunit p65 at serine 536 and of IkBa at serines 32 and 36 (Figures 1a and b) . Lapatinib also blocked NF-kB-induced gene transcription (Figure 3c ). Treatment of SKBr3 cells with lapatinib led to complete loss of phosphorylation of Akt at serine 473 (Figure 1c ), a marker for Akt activation.
To address potential contributions of IKKa and IKKb to NF-kB activation in Her2 þ cells and to the oncogenic phenotype, we used an IKK knockdown approach in Her2-overexpressing cells. Knockdown of IKKa led to a more dramatic reduction in p65 phosphorylation at Ser536 than did knockdown of IKKb (Figure 2a ). Furthermore, knockdown of IKKa strongly reduced NF-kB activation as measured through electrophoretic mobility shift assay and NF-kB-dependent reporter assays, whereas IKKb knockdown had less of an effect (Figures 2b and c) . Similarly, knockdown of IKKa was more effective at blocking IKK activity than knockdown of IKKb (Figure 2d ). SKBr3 cells show low levels of p52/NF-kB2, which is derived from IKKa-dependent processing of the p100/NF-kB2 precursor. Knockdown of IKKa had little effect on p52 levels in these cells, indicating that the non-canonical pathway does not appear to be active in SKBr3 cells at a measurable level. Consistent with this, very low to undetectable levels of p52 or RelB are detected in the nuclei of SKBr3 cells (data not shown). It is important to note that inhibition of IKKb can lead to a compensatory response whereby IKKa controls canonical NF-kB activation in some cell types (Lam et al., 2008) . Our studies clearly indicate that loss of IKKa leads to reduced NF-kB activation downstream of Her2-induced signaling. A study showing that IKKa is necessary for self-renewal of Her2-transformed mammary-initiating tumor cells (Cao et al., 2007) is consistent with our results showing the importance of IKKa in controlling NF-kB downstream of Her2. The way in which Her2 may selectively activate IKKa in breast cancer remains to be investigated. One possibility is selective activation of IKKa by the kinase NIK, as NIK has been shown to associate with ErbB2 family member EGFR (Habib et al., 2001) and has been shown to be recruited to EGF/heregulin receptor-signaling complexes (Chen et al., 2003) .
The knockdown studies were extended to analysis of NF-kB-dependent target gene expression ( Figure 3a) . Knockdown of IKKa lead to a more dramatic reduction in gene expression of IL-6, IL-8, CCL2, TNF and uPA than did knockdown of IKKb. Decreased expression of these genes upon knockdown of the p65 subunit of NF-kB indicates that this activation is occurring through the canonical pathway (Figure 3b ). To show that these genes are controlled through Her2, and not through Her2-independent pathways, lapatinib was shown to block target gene expression (Figure 3c ). This increase in chemokine and cytokine gene expression by Her2, as well as the increase in the expression of the Her2 activation of NF-jB through IKKa EC Merkhofer et al serine protease uPA, shows a large similarity to Her2induced gene expression signatures, which have been previously reported, and this increase has been implicated in progression of multiple different cancers, including breast cancer (Wang et al., 1999; Arihiro et al., 2000; Chavey et al., 2007; Vazquez-Martin et al., 2008) . Therefore, our gene expression data suggests that IKKa has an important role in regulating genes involved in breast cancer progression, and this requires the scaffolding subunit NEMO (Figure 4) . Some studies indicate that NF-kB can be activated downstream of PI3K/Akt (Makino et al., 2004; Dan et al., 2008) . However, experiments using the PI3K inhibitor LY294002 indicate that NF-kB is not activated in Her2 þ cells downstream of PI3K ( Figure 5 ). Thus, this pathway is not a link between Her2, IKKa and NF-kB activation. We cannot rule out a PI3Kindependent Akt-controlled pathway in NF-kB activation. In addition, we cannot rule out that PI3K and/or Akt have effects on NF-kB-target gene expression that function separately from the induction of NF-kB activation as assayed through experiments described above. Future studies will address Her2-regulated pathways that lead to activation of IKK. Other studies (Dillon et al., 2007) as well as our own (Figure 6b) show that activation of the PI3K pathway has an important role in cell proliferation/viability. Interestingly, knockdown of IKKa or IKKb subunits (individually or together) by siRNA has no measurable inhibitory effect on cell proliferation (Figure 6a ).
To determine if IKKa or IKKb controls other oncogenic phenotypes, we used siRNA treatment and measured cell invasion of SKBr3 cells. Her2 overexpression has been shown to induce cell invasion, consistent with its ability to promote upregulation of genes such as IL-8 and uPA (Gum et al., 1995; Vazquez-Martin et al., 2008) . Knockdown of IKKa, but not knockdown of IKKb, significantly blocks the invasive phenotype of SKBr3 cells (Figure 6c ). This result is consistent with the regulation of target genes by IKKa that are associated with invasive phenotype. Interestingly, other factors have linked breast cancer invasion and NF-kB, including microRNAs (Ma et al., 2007) . MicroRNAs have been shown to negatively regulate NF-kB activity and gene expression, such as micro-RNA-146, which can suppress expression of IL-6 and IL-8 through a reduction in levels of IRAK1 and TRAF6 in MDA-MB-231 cells, leading to the metastatic phenotype (Bhaumik et al., 2008) .
This study shows that Her2 activation of NF-kB requires IKKa, and this PI3K-independent activation leads to an increase in cytokine and chemokine Her2 activation of NF-jB through IKKa EC Merkhofer et al expression, as well as an increase in invasive phenotype (Figure 6d ). These data suggest that targeting multiple pathways in Her2 þ breast cancer may be advantageous for effective therapy, and development of inhibitors of IKKa or the use of dual IKKa/IKKb inhibitors may prove therapeutic in Her2 þ cancer cells.
Materials and methods
Cell culture and reagents
The tumor-derived SKBr3 cell lines were maintained in McCoy's 5A medium (Mediatech, Manassas, VA, USA) supplemented with 10% fetal bovine serum (FBS) and 100 units/ml penicillin/streptomycin. The tumor-derived MCF7, MDA-MB-453 and MDA-MB-231 cell lines, as well as MEF cell lines, were maintained in Dulbecco's Modified Eagle's Medium (Gibco, Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS and 100 units/ml penicillin/ streptomycin. The human mammary epithelial cell lines (H16N2-pTP and H16N2-Her2) were maintained as previously described (Ethier et al., 1993) . The stable 3 Â kB luciferase SKBr3 cell line was established by transfection of a luciferase reporter construct containing tandem NF-kB-binding sites from the MHC class I promoter region into SKBr3 cells with Fugene (Roche, Indianapolis, IN, USA) and maintained under selection with G418 (Geneticin, Sigma-Aldrich, St Louis, MO, USA). The Her2 wild-type and mutant (V654E) plasmids were constructed previously (Addgene plasmid 16257 and Addgene plasmid 16259, Addgene, Cambridge, MA, USA). The Her2 coding sequences were subcloned into retroviral pLHCX vector (Stratagene, La Jolla, CA, USA) and virus was produced in 293T cells with cotransfection of AmphoPAK. MEFs were transduced with virus with polybrene and lysed 48 h later. The following antibodies were purchased from commercial sources: antibodies against phospho-p65 (Ser 536 ), phospho-Akt (Ser 473 ), Akt, phospho-IkBa (Ser 32/36 ) and IkBa from Cell Signaling Technology (Beverly, MA, USA); antibodies against Her2, IKKa clone 14A231 and IKKb clone10AG2 and p100/p52 from Millipore (Billerica, MA, USA), antibodies against p65 and p50 (supershift), b-tubulin and IKKg from Santa Cruz Biotechnology (Santa Cruz, CA, USA), antibody against total p65 from Rockland (Gilbertsville, PA, USA) LY294002 and Wortmannin were purchased from Cell Signaling Technology. Lapatinib (GW572016; Tykerb, GSK, Brentford, Middlesex, UK) was a gift from Dr H Shelton Earp (University of North Carolina at Chapel Hill).
Immunoblots
Whole-cell extracts were prepared on ice with Mammalian Protein Extraction Reagent (Thermo Scientific, Waltham, MA, USA) according to the manufacturer's instructions supplemented with protease inhibitor mix (Roche) and phosphatase inhibitor mix (Sigma). Nuclear and cytoplasmic extracts were prepared as previously described (Mayo et al., 1997) . Protein concentrations were determined by Bradford assay (Biorad Laboratories, Hercules, CA, USA) and SDS-PAGE analysis was performed as previously described (Steinbrecher et al., 2005) .
Small RNA interference
The following small interfering RNAs (siRNA; siGenome SMARTpool) were obtained from Dharmacon (Lafayette, CO, USA) as a pool of four annealed double-stranded RNA oligonucleotides: IKKa (M-003473-02), IKKb (M-003503-03), NEMO (M-003767-02), RelA (p65) (M-003533-02) and non-targeting control no. 3 (D001201-03). Cells were grown to approximately 50% confluency and transfected with 100 nmol/l siRNA with Dharmafect 1 reagent according to the manufacturer's instructions.
Quantitative real-time PCR Total RNA extracts were obtained from cells approximately 72 h post-transfection by Trizol (Invitrogen) extraction. Two micrograms of RNA were reverse transcribed using random primers and MMLV-reverse transcriptase (Invitrogen). Real-time PCR was performed and analysed as previously described (Steinbrecher et al., 2005) using Taqman Gene Expression Assay primer-probe sets IL-6 (Hs00174131_m1), IL-8 (Hs001741103_m1), CCL2 (Hs00234140_m1), TNF (Hs99999043_m1) and uPA (Hs00170182_m1).
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay and NF-kB supershift analysis were done on nuclear extracts as previously described (Steinbrecher et al., 2005) using 32 P-labeled oligonucleotide probe corresponding to an NF-kB site within the MHC class I promoter region.
IKK kinase assay
Whole-cell lysates were prepared on ice for 45 min in lysis buffer containing 20 mmol/l Tris (pH 8.0), 500 mmol/l NaCl, 0.25% Triton X-100, 1 mmol/l EDTA, 1 mmol/l EGTA, 1 mmol/l DTT, 1 Â protease inhibitor (Roche Applied Science) and 1 Â phosphatase inhibitor cocktail (Sigma-Aldrich). IKK complexes were immunoprecipitated from 500 mg total protein extract using IKKg antibody (Santa Cruz Biotechnology). An in vitro kinase assay was done and analysed as previously described (Steinbrecher et al., 2005) using GST-IkBa as a substrate.
Luciferase assay
SKBr3 cells stably expressing the 3 Â kB plasmid were plated in equal number in triplicate in 24-well plates and transfected with siRNA for 72 h or treated overnight with LY294002. Cells were lysed in MPER and luciferase activity was measured with Promega Luciferase Assay System (Promega, Madison, WI, USA). Luciferase levels were normalized by protein concentration using a Bradford assay. H16N2-Her2 and MDA-MB-453 cells were transfected with siRNA 72 h before lysates were obtained, and were transfected with 3 Â kB reporter plasmid and pRL-CMV (Promega) renilla plasmid 24 h before lysate collection. Lysates were collected as mentioned above and luciferase levels were normalized to renilla.
Cell invasion assay
Innocyte Cell Invasion Assay Kit was purchased from Calbiochem (San Diego, California, CA, USA). Cells were transfected with siRNA for 48 h before seeding. Invasion assay was performed as per the manufacturer's protocol for 48 h. The number of invading cells was measured fluorometrically with Calcein AM.
Cell proliferation assay
Cell proliferation assay was performed as previously described (Wilson and Baldwin, 2008) . Cells were cultured in the presence or absence of inhibitors, or transiently transfected with siRNA to IKK subunits and measured at the indicated time points post-transfection.
